Cargando…

Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia

Tyrosine kinase inhibitors (TKIs) have revolutionized the management and outcomes of chronic myeloid leukemia (CML) patients. Improved disease control and prolonged life expectancy now mandate focus on improving TKIs’ safety profile. Recently, vascular adverse events (VAEs) have emerged as a serious...

Descripción completa

Detalles Bibliográficos
Autores principales: Pasvolsky, Oren, Leader, Avi, Iakobishvili, Zaza, Wasserstrum, Yishay, Kornowski, Ran, Raanani, Pia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837152/
https://www.ncbi.nlm.nih.gov/pubmed/33530148
http://dx.doi.org/10.1186/s40959-015-0008-5
_version_ 1783642901599748096
author Pasvolsky, Oren
Leader, Avi
Iakobishvili, Zaza
Wasserstrum, Yishay
Kornowski, Ran
Raanani, Pia
author_facet Pasvolsky, Oren
Leader, Avi
Iakobishvili, Zaza
Wasserstrum, Yishay
Kornowski, Ran
Raanani, Pia
author_sort Pasvolsky, Oren
collection PubMed
description Tyrosine kinase inhibitors (TKIs) have revolutionized the management and outcomes of chronic myeloid leukemia (CML) patients. Improved disease control and prolonged life expectancy now mandate focus on improving TKIs’ safety profile. Recently, vascular adverse events (VAEs) have emerged as a serious consequence of some of the newer TKIs. In this review, we describe the clinical spectrum of TKI-associated VAE, and examine the unique vascular safety profile of the main TKIs currently used in the treatment of CML: imatinib, nilotinib, dasatinib, bosutinib and ponatinib. The issue of TKI-related platelet dysfunction is discussed as well. We describe the contemporary research findings regarding the possible pathogenesis of the VAE. Finally, the different aspects of TKI-associated VAE management are addressed, including prevention methods, monitoring strategies and treatment options.
format Online
Article
Text
id pubmed-7837152
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-78371522021-01-27 Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia Pasvolsky, Oren Leader, Avi Iakobishvili, Zaza Wasserstrum, Yishay Kornowski, Ran Raanani, Pia Cardiooncology Review Tyrosine kinase inhibitors (TKIs) have revolutionized the management and outcomes of chronic myeloid leukemia (CML) patients. Improved disease control and prolonged life expectancy now mandate focus on improving TKIs’ safety profile. Recently, vascular adverse events (VAEs) have emerged as a serious consequence of some of the newer TKIs. In this review, we describe the clinical spectrum of TKI-associated VAE, and examine the unique vascular safety profile of the main TKIs currently used in the treatment of CML: imatinib, nilotinib, dasatinib, bosutinib and ponatinib. The issue of TKI-related platelet dysfunction is discussed as well. We describe the contemporary research findings regarding the possible pathogenesis of the VAE. Finally, the different aspects of TKI-associated VAE management are addressed, including prevention methods, monitoring strategies and treatment options. BioMed Central 2015-12-04 /pmc/articles/PMC7837152/ /pubmed/33530148 http://dx.doi.org/10.1186/s40959-015-0008-5 Text en © Pasvolsky et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Pasvolsky, Oren
Leader, Avi
Iakobishvili, Zaza
Wasserstrum, Yishay
Kornowski, Ran
Raanani, Pia
Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia
title Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia
title_full Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia
title_fullStr Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia
title_full_unstemmed Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia
title_short Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia
title_sort tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837152/
https://www.ncbi.nlm.nih.gov/pubmed/33530148
http://dx.doi.org/10.1186/s40959-015-0008-5
work_keys_str_mv AT pasvolskyoren tyrosinekinaseinhibitorassociatedvasculartoxicityinchronicmyeloidleukemia
AT leaderavi tyrosinekinaseinhibitorassociatedvasculartoxicityinchronicmyeloidleukemia
AT iakobishvilizaza tyrosinekinaseinhibitorassociatedvasculartoxicityinchronicmyeloidleukemia
AT wasserstrumyishay tyrosinekinaseinhibitorassociatedvasculartoxicityinchronicmyeloidleukemia
AT kornowskiran tyrosinekinaseinhibitorassociatedvasculartoxicityinchronicmyeloidleukemia
AT raananipia tyrosinekinaseinhibitorassociatedvasculartoxicityinchronicmyeloidleukemia